Gene basic information

Tissuebone marrow,
CancerB-cell lymphoma,


The alternative splicing of Fas in lymphomas is tightly regulated by a long-noncoding RNA FAS-AS1. Level of FAS-AS1 correlates inversely with production of sFas, and FAS-AS1 binding to the RBM5 inhibits RBM5-mediated exon 6 skipping. EZH2 hyper-methylates the FAS-AS1 promoter and represses the FAS-AS1 expression. EZH2-mediated repression of FAS-AS1 promoter can be released by DZNeP (3-Deazaneplanocin A) or overcome by ectopic expression of FAS-AS1, both of which increase the expression level of FAS-AS1 and correspondingly decrease expression of sFas. Treatment with Bruton's tyrosine kinase inhibitor or EZH2 knockdown decreases the level of EZH2, RBM5 and sFas, thereby enhancing Fas-mediated apoptosis (1).

Cancer related information

download as excel csv txt

LncRNA tissue cancer type expression level oncogene/suppress gene pathway binding gene/factor associated gene/factor proliferation apoptosis migration EMT invasion metastasis prognosis tag PMID
0 FAS-AS1 bone marrow B-cell lymphoma / / RBM5 sFas-,-EZH2 24811343

Expression profile

adipose adrenal brain breast colon heart kidney leukocyte liver lung lymph node ovary prostate skeletal muscle testis thyroid tissue 0.00 0.05 0.10 0.15 0.20 0.25 0.30 fpkm 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 FAS-AS1

Expression profile in human body map

Genomic feature visualization



[1]. Sehgal L, Mathur R, Braun FK, Wise JF, Berkova Z, et al. (2014). FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma. Leukemia 28(12): 2376-87. link pubmed

© Bioinformatics Group of XTBG